Find clinical trials for Acute Myeloid Leukemia (AML) in New York, NY
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
Acute Myeloid Leukemia (AML) trials near New York, NY, USA:
The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute...
Phase 3
New York, New York, United States and 125 other locations
The main objective of this study is to evaluate the efficacy of venetoclax in combination with azacitidine to improve Overall Survival (OS) in Acute...
Phase 3
New York, New York, United States and 164 other locations
Acute myeloid leukemia (AML) is the second most common type of leukemia diagnosed in adults and children ...
Phase 1
New York, New York, United States and 14 other locations
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid...
Phase 1
New York, New York, United States and 6 other locations
People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML hav...
Phase 1, Phase 2
Bronx, New York, United States and 17 other locations
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid...
Phase 3
New York, New York, United States and 23 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of JNJ-75276617 in combination with AML directed ...
Phase 1
New York, New York, United States and 29 other locations
Antisense Oligodeoxynucleotide) in patients with refractory/relapsed AML. The study is designed to assess the safety profile, identify DLTs,...
Phase 1
New York, New York, United States and 3 other locations
A Phase 1/2 dose escalation study of BCL-2 Inhibitor ZN-d5 and the Wee1 Inhibitor ZN-c3 in Subjects with Acute Myeloid Leukemia...
Phase 1, Phase 2
New York, New York, United States and 12 other locations
a safe and effective treatment for people with relapsed/refractory AML with FLT3/IDH1 or FLT3/IDH2 gene mutations. The researchers will also...
Phase 1
New York, New York, United States and 6 other locations
Clinical trials
Research sites
Resources
Legal